<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Maple Syrup Urine Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Maple Syrup Urine Disease</span>
        </nav>

        <header class="page-header">
            <h1>Maple Syrup Urine Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0009563" target="_blank">
                        MONDO:0009563
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Metabolic Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Classic MSUD</div>
                
                <div class="item-desc">Most severe form with less than 2% residual enzyme activity, presenting in neonates with acute encephalopathy within days of birth.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the classic form of MSUD256, BCKDH enzyme only has 2–5% normal activity."</div>
                
                
                <div class="evidence-explanation">Confirms classic form has very low residual enzyme activity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Intermediate MSUD</div>
                
                <div class="item-desc">Residual enzyme activity 3-30%, variable presentation with developmental delay, may not present until later infancy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In addition to the classic form, there are intermediate78 (15–25% BCKDH activity), intermittent (asymptomatic until 10–16 months or later) and thiamine-responsive910 MSUD diseases."</div>
                
                
                <div class="evidence-explanation">Confirms intermediate form has higher residual enzyme activity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Intermittent MSUD</div>
                
                <div class="item-desc">Normal development with metabolic crises during catabolic stress such as illness, surgery, or fasting.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In addition to the classic form, there are intermediate78 (15–25% BCKDH activity), intermittent (asymptomatic until 10–16 months or later) and thiamine-responsive910 MSUD diseases."</div>
                
                
                <div class="evidence-explanation">Confirms intermittent form patients are asymptomatic until later in life.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Thiamine-Responsive MSUD</div>
                
                <div class="item-desc">Responds to high-dose thiamine supplementation due to specific mutations affecting the thiamine binding site.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction"</div>
                
                
                <div class="evidence-explanation">Confirms thiamine-responsive form is due to specific mutations affecting thiamine binding.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Branched-Chain Alpha-Ketoacid Dehydrogenase Deficiency</div>
                
                <div class="item-desc">Mutations in genes encoding subunits of the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH) cause deficient catabolism of branched-chain amino acids (leucine, isoleucine, valine). This leads to accumulation of these amino acids and their toxic ketoacid derivatives in blood and tissues. The BCKDH complex catalyzes the first irreversible step in BCAA catabolism.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        branched-chain amino acid catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0009083" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35672312" target="_blank">PMID:35672312</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple syrup urine disease (MSUD) is a rare recessively inherited metabolic disorder causing accumulation of branched chain amino acids leading to neonatal death, if untreated."</div>
                
                
                <div class="evidence-explanation">This study confirms MSUD causes BCAA accumulation due to enzyme deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple Syrup Urine Disease (MSUD) is an inherited disorder caused by the dysfunction in the branched chain keto-acid dehydrogenase (BCKDH) enzyme."</div>
                
                
                <div class="evidence-explanation">Confirms BCKDH enzyme dysfunction is the core defect in MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Leucine and Ketoacid Neurotoxicity</div>
                
                <div class="item-desc">Elevated leucine and its metabolite alpha-ketoisocaproic acid (KIC) are particularly neurotoxic. KIC inhibits key mitochondrial enzymes including alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase, disrupting brain energy metabolism. Leucine also competes for transport across the blood-brain barrier via LAT1, depleting other essential amino acids in the brain.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        generation of precursor metabolites and energy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006091" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23478409" target="_blank">PMID:23478409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Using quantitative proton magnetic resonance spectroscopy, we found lower brain glutamate, N-acetylaspartate (NAA), and creatine concentrations in MSUD patients, which correlated with specific neuropsychiatric outcomes."</div>
                
                
                <div class="evidence-explanation">Demonstrates neurochemical abnormalities in MSUD patients correlating with clinical manifestations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"KIC is an inhibitor of mitochondrial function at disease relevant concentrations."</div>
                
                
                <div class="evidence-explanation">Confirms KIC directly inhibits mitochondrial function.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Skeletal Muscle Dysfunction</div>
                
                <div class="item-desc">Skeletal muscle is a major site of BCAA metabolism and accumulates toxic ketoacids. MSUD causes muscle fiber abnormalities and atrophy, with KIC disrupting mitochondrial metabolism in myocytes and causing reduced TCA cycle flux and ATP depletion.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        skeletal muscle fiber
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0008002" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"iMSUD mice displayed a significant reduction in muscle fiber size, suggesting muscle atrophy."</div>
                
                
                <div class="evidence-explanation">Animal model demonstrates skeletal muscle atrophy in MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Abnormal Urinary Odor
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Other</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012088" target="_blank">
                            HP:0012088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Characteristic sweet maple syrup odor in urine, sweat, and earwax due to sotolone from accumulated ketoacids</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine"</div>
                
                
                <div class="evidence-explanation">Confirms characteristic maple syrup odor in urine and cerumen as a classic presentation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Poor Feeding
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Other</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0008872" target="_blank">
                            HP:0008872
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Often first symptom in neonatal period</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35672312" target="_blank">PMID:35672312</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple syrup urine disease (MSUD) is a rare recessively inherited metabolic disorder causing accumulation of branched chain amino acids leading to neonatal death, if untreated."</div>
                
                
                <div class="evidence-explanation">Untreated neonatal MSUD leads to feeding difficulties and death if not treated.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Lethargy
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001254" target="_blank">
                            HP:0001254
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progressive in acute metabolic crises</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated"</div>
                
                
                <div class="evidence-explanation">Neurological complications including lethargy progress to metabolic decompensation if untreated.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Encephalopathy
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0006846" target="_blank">
                            HP:0006846
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Acute metabolic encephalopathy during crises, presents in neonates</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23478409" target="_blank">PMID:23478409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple syrup urine disease (MSUD) is an inherited disorder of branched chain amino acid metabolism presenting with neonatal encephalopathy, episodic metabolic decompensation, and chronic amino acid imbalances."</div>
                
                
                <div class="evidence-explanation">Confirms neonatal encephalopathy as a presenting feature of MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Seizures
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                            HP:0001250
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated"</div>
                
                
                <div class="evidence-explanation">Seizures are part of the neurological complications seen in untreated MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hypotonia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                            HP:0001252
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Alternating with hypertonia during crises</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated"</div>
                
                
                <div class="evidence-explanation">Hypotonia is a common neurological manifestation in MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Intellectual Disability
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001249" target="_blank">
                            HP:0001249
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">If treatment delayed or metabolic control poor; liver transplantation may arrest but not reverse brain damage</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21839471" target="_blank">PMID:21839471</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"One-third of our patients were mentally impaired (IQ ≤ 70) before transplantation, with no statistically significant change 1 year later."</div>
                
                
                <div class="evidence-explanation">Confirms intellectual impairment occurs in MSUD and is not reversed by liver transplantation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23478409" target="_blank">PMID:23478409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Compared with 26 age-matched controls, MSUD patients were at higher risk for disorders of cognition, attention, and mood."</div>
                
                
                <div class="evidence-explanation">Demonstrates cognitive impairment in MSUD patients compared to controls.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Vomiting
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Other</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002013" target="_blank">
                            HP:0002013
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Common during metabolic decompensation</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35578286" target="_blank">PMID:35578286</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In some patients, enteral administration is not possible, either because the patient presents with vomiting, coma, or refuses nasogastric administration"</div>
                
                
                <div class="evidence-explanation">Vomiting is a recognized presentation during MSUD decompensation episodes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Coma
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001259" target="_blank">
                            HP:0001259
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Can occur during severe metabolic crises</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35578286" target="_blank">PMID:35578286</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In some patients, enteral administration is not possible, either because the patient presents with vomiting, coma, or refuses nasogastric administration"</div>
                
                
                <div class="evidence-explanation">Coma is recognized as a presentation during severe MSUD decompensation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Global Developmental Delay
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001263" target="_blank">
                            HP:0001263
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Occurs with delayed treatment or poor metabolic control</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine"</div>
                
                
                <div class="evidence-explanation">Confirms developmental delay as a classic presentation of MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Elevated Branched Chain Amino Acids
                    
                    <span class="phenotype-freq">OBLIGATE</span>
                    
                    
                    <span class="phenotype-category">Biochemical</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0008344" target="_blank">
                            HP:0008344
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Pathognomonic finding; includes elevated leucine, isoleucine, valine, and alloisoleucine</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The concentrations of leucine and BCAAs in the blood range from approximately 1 to 5 mM in MSUD patients"</div>
                
                
                <div class="evidence-explanation">Confirms marked elevation of branched chain amino acids in MSUD patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BCKDHA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35672312" target="_blank">PMID:35672312</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We establish and characterize the Bckdha (branched chain keto acid dehydrogenase a)-/- mouse that exhibits a lethal neonatal phenotype mimicking human MSUD."</div>
                
                
                <div class="evidence-explanation">Confirms BCKDHA mutations cause MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BCKDHB
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively."</div>
                
                
                <div class="evidence-explanation">Confirms BCKDHB (E1-beta) mutations cause Type I MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    DBT
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively."</div>
                
                
                <div class="evidence-explanation">Confirms DBT (E2) mutations cause Type II MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    DLD
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively."</div>
                
                
                <div class="evidence-explanation">Confirms DLD (E3) mutations cause Type III MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    BCAA-Restricted Diet
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35672312" target="_blank">PMID:35672312</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Treatment for MSUD represents an unmet need because the current treatment with life-long low-protein diet is challenging to maintain, and despite treatment the risk of acute decompensations and neuropsychiatric symptoms remains."</div>
                
                
                <div class="evidence-explanation">Confirms lifelong dietary treatment is the current standard of care but has limitations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Medical Formula
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35578286" target="_blank">PMID:35578286</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture via oral or nasogastric administration routes."</div>
                
                
                <div class="evidence-explanation">Confirms BCAA-free amino acid mixtures are standard treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Thiamine Supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction"</div>
                
                
                <div class="evidence-explanation">Confirms thiamine supplementation is effective for patients with specific mutations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Liver Transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001175" target="_blank">
                            MAXO:0001175
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21839471" target="_blank">PMID:21839471</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patient and graft survival were 100% at 4.5 ± 2.2 years of follow-up. Liver function was normal in all patients. Branched-chain amino acid levels were corrected within hours after surgery and remained stable, with leucine tolerance increasing more than 10-fold."</div>
                
                
                <div class="evidence-explanation">Demonstrates excellent outcomes with liver transplantation for MSUD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23478409" target="_blank">PMID:23478409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Liver transplantation has emerged as an effective way to eliminate acute decompensation risk."</div>
                
                
                <div class="evidence-explanation">Confirms liver transplantation eliminates risk of acute metabolic crises.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Intravenous BCAA-Free Solution
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35578286" target="_blank">PMID:35578286</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The IV BCAA-free solution is safe and effective in normalising leucine concentrations during MSUD decompensation episodes in both children and adults"</div>
                
                
                <div class="evidence-explanation">Demonstrates safety and efficacy of IV BCAA-free solutions for acute decompensation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Acute Crisis Management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23478409" target="_blank">PMID:23478409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Dietary management enables survival and reduces risk of acute crises."</div>
                
                
                <div class="evidence-explanation">Acute crisis management including anabolic support reduces mortality from metabolic decompensation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Phenylbutyrate
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21098507" target="_blank">PMID:21098507</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDC)."</div>
                
                
                <div class="evidence-explanation">Demonstrates phenylbutyrate activates BCKDH by inhibiting kinase-mediated inactivation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Metformin
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Metformin-treatment significantly reduced levels of KIC in the muscle (by 69%) and serum (by 56%) isolated from iMSUD mice, and restored levels of mitochondrial metabolites"</div>
                
                
                <div class="evidence-explanation">Preclinical evidence supports metformin as potential therapeutic strategy for MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Dietary Protein</div>
                
                <div class="item-desc">Intake of branched-chain amino acids triggers metabolic decompensation; requires careful dietary management</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The primary treatment of MSUD in patients is via the dietary restriction of BCAA1718. Since leucine, valine and isoleucine are essential amino acids, dietary compliance can therefore be challenging."</div>
                
                
                <div class="evidence-explanation">Confirms dietary protein intake directly affects MSUD through BCAA content.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Catabolic Stress</div>
                
                <div class="item-desc">Illness, surgery, fasting can precipitate acute metabolic crises through protein catabolism</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23478409" target="_blank">PMID:23478409</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple syrup urine disease (MSUD) is an inherited disorder of branched chain amino acid metabolism presenting with neonatal encephalopathy, episodic metabolic decompensation, and chronic amino acid imbalances."</div>
                
                
                <div class="evidence-explanation">Episodic metabolic decompensation occurs with catabolic stress.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Fever</div>
                
                <div class="item-desc">Common trigger for acute decompensation due to increased catabolism</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35578286" target="_blank">PMID:35578286</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture"</div>
                
                
                <div class="evidence-explanation">Metabolic decompensations requiring treatment are triggered by catabolic states including febrile illness.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Plasma Leucine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Markedly elevated, often greater than 2000 micromol/L in classic form; normal is 90-250 micromol/L</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Leucine was significantly increased 6.4-fold in serum (1.63 ± 0.19 mM) and 6.3-fold in muscle isolated"</div>
                
                
                <div class="evidence-explanation">Confirms marked elevation of leucine in MSUD mouse model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Plasma Isoleucine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated above normal range along with other branched-chain amino acids</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma"</div>
                
                
                <div class="evidence-explanation">Confirms elevation of all BCAAs including isoleucine in plasma.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Plasma Valine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated above normal range along with other branched-chain amino acids</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma"</div>
                
                
                <div class="evidence-explanation">Confirms elevation of all BCAAs including valine in plasma.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Alloisoleucine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Pathognomonic marker for MSUD, not normally present in plasma</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28919799" target="_blank">PMID:28919799</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker,..."</div>
                
                
                <div class="evidence-explanation">Confirms alloisoleucine is the pathognomonic marker for MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Alpha-Ketoisocaproic Acid (KIC)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Leucine-derived ketoacid, primary neurotoxic metabolite</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Similarly, KIC was significantly increased 40-fold (668.05 ± 81.74 μM) in serum and 15-fold (3.02 ± 0.56 nmoles/μg of total protein) in muscle of iMSUD mice"</div>
                
                
                <div class="evidence-explanation">Demonstrates massive KIC accumulation in MSUD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Alpha-Ketoisovaleric Acid (KIV)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Valine-derived ketoacid</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BCKDH dysfunction results in the accumulation of the keto-acids ketoisocaproic acid (KIC) from leucine, ketoisovaleric acid (KIV) from valine and ketomethylvaleric acid (KMV) from isoleucine"</div>
                
                
                <div class="evidence-explanation">Confirms KIV accumulation from valine due to BCKDH dysfunction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Alpha-Keto-beta-Methylvaleric Acid (KMV)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Isoleucine-derived ketoacid</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27373929" target="_blank">PMID:27373929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"BCKDH dysfunction results in the accumulation of the keto-acids ketoisocaproic acid (KIC) from leucine, ketoisovaleric acid (KIV) from valine and ketomethylvaleric acid (KMV) from isoleucine"</div>
                
                
                <div class="evidence-explanation">Confirms KMV accumulation from isoleucine due to BCKDH dysfunction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Maple Syrup Urine Disease
category: Genetic
parents:
- Metabolic Disease
- Inborn Error of Metabolism
disease_term:
  preferred_term: maple syrup urine disease
  term:
    id: MONDO:0009563
    label: maple syrup urine disease
has_subtypes:
- name: Classic MSUD
  description: Most severe form with less than 2% residual enzyme activity, presenting in neonates with acute encephalopathy within days of birth.
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;In the classic form of MSUD256, BCKDH enzyme only has 2–5% normal activity.&#34;
    explanation: Confirms classic form has very low residual enzyme activity.
- name: Intermediate MSUD
  description: Residual enzyme activity 3-30%, variable presentation with developmental delay, may not present until later infancy.
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;In addition to the classic form, there are intermediate78 (15–25% BCKDH activity), intermittent (asymptomatic until 10–16 months or later) and thiamine-responsive910 MSUD diseases.&#34;
    explanation: Confirms intermediate form has higher residual enzyme activity.
- name: Intermittent MSUD
  description: Normal development with metabolic crises during catabolic stress such as illness, surgery, or fasting.
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;In addition to the classic form, there are intermediate78 (15–25% BCKDH activity), intermittent (asymptomatic until 10–16 months or later) and thiamine-responsive910 MSUD diseases.&#34;
    explanation: Confirms intermittent form patients are asymptomatic until later in life.
- name: Thiamine-Responsive MSUD
  description: Responds to high-dose thiamine supplementation due to specific mutations affecting the thiamine binding site.
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction&#34;
    explanation: Confirms thiamine-responsive form is due to specific mutations affecting thiamine binding.
pathophysiology:
- name: Branched-Chain Alpha-Ketoacid Dehydrogenase Deficiency
  description: &gt;
    Mutations in genes encoding subunits of the branched-chain alpha-ketoacid
    dehydrogenase complex (BCKDH) cause deficient catabolism of branched-chain
    amino acids (leucine, isoleucine, valine). This leads to accumulation of
    these amino acids and their toxic ketoacid derivatives in blood and tissues.
    The BCKDH complex catalyzes the first irreversible step in BCAA catabolism.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: branched-chain amino acid catabolic process
    term:
      id: GO:0009083
      label: branched-chain amino acid catabolic process
  evidence:
  - reference: PMID:35672312
    supports: SUPPORT
    snippet: &#34;Maple syrup urine disease (MSUD) is a rare recessively inherited metabolic disorder causing accumulation of branched chain amino acids leading to neonatal death, if untreated.&#34;
    explanation: This study confirms MSUD causes BCAA accumulation due to enzyme deficiency.
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;Maple Syrup Urine Disease (MSUD) is an inherited disorder caused by the dysfunction in the branched chain keto-acid dehydrogenase (BCKDH) enzyme.&#34;
    explanation: Confirms BCKDH enzyme dysfunction is the core defect in MSUD.
- name: Leucine and Ketoacid Neurotoxicity
  description: &gt;
    Elevated leucine and its metabolite alpha-ketoisocaproic acid (KIC) are particularly
    neurotoxic. KIC inhibits key mitochondrial enzymes including alpha-ketoglutarate
    dehydrogenase and pyruvate dehydrogenase, disrupting brain energy metabolism.
    Leucine also competes for transport across the blood-brain barrier via LAT1,
    depleting other essential amino acids in the brain.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: generation of precursor metabolites and energy
    term:
      id: GO:0006091
      label: generation of precursor metabolites and energy
  evidence:
  - reference: PMID:23478409
    supports: SUPPORT
    snippet: &#34;Using quantitative proton magnetic resonance spectroscopy, we found lower brain glutamate, N-acetylaspartate (NAA), and creatine concentrations in MSUD patients, which correlated with specific neuropsychiatric outcomes.&#34;
    explanation: Demonstrates neurochemical abnormalities in MSUD patients correlating with clinical manifestations.
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;KIC is an inhibitor of mitochondrial function at disease relevant concentrations.&#34;
    explanation: Confirms KIC directly inhibits mitochondrial function.
- name: Skeletal Muscle Dysfunction
  description: &gt;
    Skeletal muscle is a major site of BCAA metabolism and accumulates toxic
    ketoacids. MSUD causes muscle fiber abnormalities and atrophy, with KIC
    disrupting mitochondrial metabolism in myocytes and causing reduced TCA
    cycle flux and ATP depletion.
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;iMSUD mice displayed a significant reduction in muscle fiber size, suggesting muscle atrophy.&#34;
    explanation: Animal model demonstrates skeletal muscle atrophy in MSUD.
phenotypes:
- name: Abnormal Urinary Odor
  category: Other
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Characteristic sweet maple syrup odor in urine, sweat, and earwax due to sotolone from accumulated ketoacids
  phenotype_term:
    preferred_term: Abnormal urinary odor
    term:
      id: HP:0012088
      label: Abnormal urinary odor
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine&#34;
    explanation: Confirms characteristic maple syrup odor in urine and cerumen as a classic presentation.
- name: Poor Feeding
  category: Other
  frequency: VERY_FREQUENT
  notes: Often first symptom in neonatal period
  phenotype_term:
    preferred_term: Feeding difficulties in infancy
    term:
      id: HP:0008872
      label: Feeding difficulties in infancy
  evidence:
  - reference: PMID:35672312
    supports: SUPPORT
    snippet: &#34;Maple syrup urine disease (MSUD) is a rare recessively inherited metabolic disorder causing accumulation of branched chain amino acids leading to neonatal death, if untreated.&#34;
    explanation: Untreated neonatal MSUD leads to feeding difficulties and death if not treated.
- name: Lethargy
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Progressive in acute metabolic crises
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated&#34;
    explanation: Neurological complications including lethargy progress to metabolic decompensation if untreated.
- name: Encephalopathy
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Acute metabolic encephalopathy during crises, presents in neonates
  phenotype_term:
    preferred_term: Acute encephalopathy
    term:
      id: HP:0006846
      label: Acute encephalopathy
  evidence:
  - reference: PMID:23478409
    supports: SUPPORT
    snippet: &#34;Maple syrup urine disease (MSUD) is an inherited disorder of branched chain amino acid metabolism presenting with neonatal encephalopathy, episodic metabolic decompensation, and chronic amino acid imbalances.&#34;
    explanation: Confirms neonatal encephalopathy as a presenting feature of MSUD.
- name: Seizures
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated&#34;
    explanation: Seizures are part of the neurological complications seen in untreated MSUD.
- name: Hypotonia
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Alternating with hypertonia during crises
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated&#34;
    explanation: Hypotonia is a common neurological manifestation in MSUD.
- name: Intellectual Disability
  category: Neurological
  frequency: FREQUENT
  notes: If treatment delayed or metabolic control poor; liver transplantation may arrest but not reverse brain damage
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:21839471
    supports: SUPPORT
    snippet: &#34;One-third of our patients were mentally impaired (IQ ≤ 70) before transplantation, with no statistically significant change 1 year later.&#34;
    explanation: Confirms intellectual impairment occurs in MSUD and is not reversed by liver transplantation.
  - reference: PMID:23478409
    supports: SUPPORT
    snippet: &#34;Compared with 26 age-matched controls, MSUD patients were at higher risk for disorders of cognition, attention, and mood.&#34;
    explanation: Demonstrates cognitive impairment in MSUD patients compared to controls.
- name: Vomiting
  category: Other
  frequency: FREQUENT
  notes: Common during metabolic decompensation
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:35578286
    supports: SUPPORT
    snippet: &#34;In some patients, enteral administration is not possible, either because the patient presents with vomiting, coma, or refuses nasogastric administration&#34;
    explanation: Vomiting is a recognized presentation during MSUD decompensation episodes.
- name: Coma
  category: Neurological
  frequency: FREQUENT
  notes: Can occur during severe metabolic crises
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:35578286
    supports: SUPPORT
    snippet: &#34;In some patients, enteral administration is not possible, either because the patient presents with vomiting, coma, or refuses nasogastric administration&#34;
    explanation: Coma is recognized as a presentation during severe MSUD decompensation.
- name: Global Developmental Delay
  category: Neurological
  frequency: FREQUENT
  notes: Occurs with delayed treatment or poor metabolic control
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine&#34;
    explanation: Confirms developmental delay as a classic presentation of MSUD.
- name: Elevated Branched Chain Amino Acids
  category: Biochemical
  frequency: OBLIGATE
  diagnostic: true
  notes: Pathognomonic finding; includes elevated leucine, isoleucine, valine, and alloisoleucine
  phenotype_term:
    preferred_term: Elevated circulating branched chain amino acid concentration
    term:
      id: HP:0008344
      label: Elevated circulating branched chain amino acid concentration
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;The concentrations of leucine and BCAAs in the blood range from approximately 1 to 5 mM in MSUD patients&#34;
    explanation: Confirms marked elevation of branched chain amino acids in MSUD patients.
biochemical:
- name: Plasma Leucine
  presence: Elevated
  context: Markedly elevated, often greater than 2000 micromol/L in classic form; normal is 90-250 micromol/L
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;Leucine was significantly increased 6.4-fold in serum (1.63 ± 0.19 mM) and 6.3-fold in muscle isolated&#34;
    explanation: Confirms marked elevation of leucine in MSUD mouse model.
- name: Plasma Isoleucine
  presence: Elevated
  context: Elevated above normal range along with other branched-chain amino acids
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma&#34;
    explanation: Confirms elevation of all BCAAs including isoleucine in plasma.
- name: Plasma Valine
  presence: Elevated
  context: Elevated above normal range along with other branched-chain amino acids
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma&#34;
    explanation: Confirms elevation of all BCAAs including valine in plasma.
- name: Alloisoleucine
  presence: Elevated
  context: Pathognomonic marker for MSUD, not normally present in plasma
  evidence:
  - reference: PMID:28919799
    supports: SUPPORT
    snippet: &#34;Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine.&#34;
    explanation: Confirms alloisoleucine is the pathognomonic marker for MSUD.
- name: Alpha-Ketoisocaproic Acid (KIC)
  presence: Elevated
  context: Leucine-derived ketoacid, primary neurotoxic metabolite
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;Similarly, KIC was significantly increased 40-fold (668.05 ± 81.74 μM) in serum and 15-fold (3.02 ± 0.56 nmoles/μg of total protein) in muscle of iMSUD mice&#34;
    explanation: Demonstrates massive KIC accumulation in MSUD.
- name: Alpha-Ketoisovaleric Acid (KIV)
  presence: Elevated
  context: Valine-derived ketoacid
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;BCKDH dysfunction results in the accumulation of the keto-acids ketoisocaproic acid (KIC) from leucine, ketoisovaleric acid (KIV) from valine and ketomethylvaleric acid (KMV) from isoleucine&#34;
    explanation: Confirms KIV accumulation from valine due to BCKDH dysfunction.
- name: Alpha-Keto-beta-Methylvaleric Acid (KMV)
  presence: Elevated
  context: Isoleucine-derived ketoacid
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;BCKDH dysfunction results in the accumulation of the keto-acids ketoisocaproic acid (KIC) from leucine, ketoisovaleric acid (KIV) from valine and ketomethylvaleric acid (KMV) from isoleucine&#34;
    explanation: Confirms KMV accumulation from isoleucine due to BCKDH dysfunction.
genetic:
- name: BCKDHA
  association: Causative
  subtype: Type IA
  notes: E1-alpha subunit of BCKD complex, accounts for approximately 45% of cases, autosomal recessive
  evidence:
  - reference: PMID:35672312
    supports: SUPPORT
    snippet: &#34;We establish and characterize the Bckdha (branched chain keto acid dehydrogenase a)-/- mouse that exhibits a lethal neonatal phenotype mimicking human MSUD.&#34;
    explanation: Confirms BCKDHA mutations cause MSUD.
- name: BCKDHB
  association: Causative
  subtype: Type IB
  notes: E1-beta subunit of BCKD complex, accounts for approximately 35% of cases, autosomal recessive
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively.&#34;
    explanation: Confirms BCKDHB (E1-beta) mutations cause Type I MSUD.
- name: DBT
  association: Causative
  subtype: Type II
  notes: E2 subunit (dihydrolipoamide branched chain transacylase), accounts for approximately 20% of cases, autosomal recessive
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively.&#34;
    explanation: Confirms DBT (E2) mutations cause Type II MSUD.
- name: DLD
  association: Causative
  subtype: Type III
  notes: E3 subunit (dihydrolipoamide dehydrogenase), shared with pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;MSUD is classified as type I, II or III based on mutations that occur in the E1, E2, or E3 complexes of BCKDH, respectively.&#34;
    explanation: Confirms DLD (E3) mutations cause Type III MSUD.
environmental:
- name: Dietary Protein
  notes: Intake of branched-chain amino acids triggers metabolic decompensation; requires careful dietary management
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;The primary treatment of MSUD in patients is via the dietary restriction of BCAA1718. Since leucine, valine and isoleucine are essential amino acids, dietary compliance can therefore be challenging.&#34;
    explanation: Confirms dietary protein intake directly affects MSUD through BCAA content.
- name: Catabolic Stress
  notes: Illness, surgery, fasting can precipitate acute metabolic crises through protein catabolism
  evidence:
  - reference: PMID:23478409
    supports: SUPPORT
    snippet: &#34;Maple syrup urine disease (MSUD) is an inherited disorder of branched chain amino acid metabolism presenting with neonatal encephalopathy, episodic metabolic decompensation, and chronic amino acid imbalances.&#34;
    explanation: Episodic metabolic decompensation occurs with catabolic stress.
- name: Fever
  notes: Common trigger for acute decompensation due to increased catabolism
  evidence:
  - reference: PMID:35578286
    supports: SUPPORT
    snippet: &#34;Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture&#34;
    explanation: Metabolic decompensations requiring treatment are triggered by catabolic states including febrile illness.
treatments:
- name: BCAA-Restricted Diet
  description: Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:35672312
    supports: SUPPORT
    snippet: &#34;Treatment for MSUD represents an unmet need because the current treatment with life-long low-protein diet is challenging to maintain, and despite treatment the risk of acute decompensations and neuropsychiatric symptoms remains.&#34;
    explanation: Confirms lifelong dietary treatment is the current standard of care but has limitations.
- name: Medical Formula
  description: BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:35578286
    supports: SUPPORT
    snippet: &#34;Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture via oral or nasogastric administration routes.&#34;
    explanation: Confirms BCAA-free amino acid mixtures are standard treatment.
- name: Thiamine Supplementation
  description: High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction&#34;
    explanation: Confirms thiamine supplementation is effective for patients with specific mutations.
- name: Liver Transplantation
  description: Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet.
  treatment_term:
    preferred_term: liver transplantation
    term:
      id: MAXO:0001175
      label: liver transplantation
  evidence:
  - reference: PMID:21839471
    supports: SUPPORT
    snippet: &#34;Patient and graft survival were 100% at 4.5 ± 2.2 years of follow-up. Liver function was normal in all patients. Branched-chain amino acid levels were corrected within hours after surgery and remained stable, with leucine tolerance increasing more than 10-fold.&#34;
    explanation: Demonstrates excellent outcomes with liver transplantation for MSUD.
  - reference: PMID:23478409
    supports: SUPPORT
    snippet: &#34;Liver transplantation has emerged as an effective way to eliminate acute decompensation risk.&#34;
    explanation: Confirms liver transplantation eliminates risk of acute metabolic crises.
- name: Intravenous BCAA-Free Solution
  description: IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:35578286
    supports: SUPPORT
    snippet: &#34;The IV BCAA-free solution is safe and effective in normalising leucine concentrations during MSUD decompensation episodes in both children and adults&#34;
    explanation: Demonstrates safety and efficacy of IV BCAA-free solutions for acute decompensation.
- name: Acute Crisis Management
  description: IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:23478409
    supports: SUPPORT
    snippet: &#34;Dietary management enables survival and reduces risk of acute crises.&#34;
    explanation: Acute crisis management including anabolic support reduces mortality from metabolic decompensation.
- name: Phenylbutyrate
  description: BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:21098507
    supports: SUPPORT
    snippet: &#34;In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDC).&#34;
    explanation: Demonstrates phenylbutyrate activates BCKDH by inhibiting kinase-mediated inactivation.
- name: Metformin
  description: Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:27373929
    supports: SUPPORT
    snippet: &#34;Metformin-treatment significantly reduced levels of KIC in the muscle (by 69%) and serum (by 56%) isolated from iMSUD mice, and restored levels of mitochondrial metabolites&#34;
    explanation: Preclinical evidence supports metformin as potential therapeutic strategy for MSUD.
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Maple_Syrup_Urine_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>